Clinical trials: Hepatitis, Viral, Human
Hepatitis B, Chronic
Effect of RO6871765 and RO7011785 on Immune Response With the Stimulation of Peripheral Blood Mononuclear Cells (PBMCs) in Chinese Healthy Volunteers and Chronic Hepatitis B Patients
This is an exploratory study to characterize the ex vivo immune response to RO6871765 or RO7011785 stimulation of peripheral blood mononuclear cells (PBMCs) extracted from healthy volunteers and chronic hepatitis B (CHB) patients.
- Trial name
- NCT02498275
- Where
- 3 sites in China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
The Effect of Entecavir Consolidation on Post-TDF Treatment Durability
Clinical relapse occurred much earlier and tended to be more severe after cessation of TDF than ETV. The follow-up interval and intensity would be different between ETV and TDF after discontinuation of therapy.
- Trial name
- NCT03308890
- Testing
- 0.5mg Baraclude(entecavir)
- Volunteers
- 156 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hepatitis E
Exposure to Hepatitis E Virus in Occitania, France
The objective of the proposed work is to determine the seroprevalence of HEV in 2023 in a population of blood donors living in Occitania. Compare the current frequency of anti-HEV IgG and IgM markers with that of 2011.
- Trial name
- EVE (NCT06137313)
- Testing
- questionnaire
- Where
- France
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Hepatitis C
SMV + SOF With/Without RBV for IFN-II Patients With CHC
Prior trials have shown that many G1 CHC patients are ineligible or intolerant to pegylated (PEG)-based regimens due to prior severe side effects, worsening of cytopenias, exacerbation of underlying psychiatric disorders, or…
- Trial name
- NCT02214420
- Testing
- Simeprevir, Sofosbuvir, Ribavirin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- SC Liver Research Consortium, LLC
Hepatitis C, Hepatitis C, Chronic
Anticipated and Perceived Benefits Following Hepatitis C Treatment
The study is both qualitative and quantitative, gathering patient's perceptions of HCV treatment benefits before and after HCV treatment by administering surveys and conducting in-depth qualitative patient interviews.
- Trial name
- NCT03000023
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of North Carolina, Chapel Hill
Hepatitis C, Chronic
Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)
This is a single-arm, multicenter study of boceprevir (BOC) in combination with peginterferon plus ribavirin (PEG/RBV) in adult chronic hepatitis C (CHC) genotype 1 participants who completed their per-protocol defined treatment…
- Trial name
- PROVIDE (NCT00910624)
- Testing
- Boceprevir, Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 168 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis B
A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.
A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.
- Trial name
- NCT07600788
- Testing
- AHB-137 injection
- Where
- 5 sites in China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ausper Biopharma Co., Ltd.
Hepatitis C, Chronic
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
Follow-up for viral activity, changes in liver function and safety in patients with no SVR24 in feeder studies
- Trial name
- NCT02465203
- Testing
- Previous treatment in DEB025 study
- Where
- 40 sites in United States, Australia and 14 more
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Poliomyelitis, Tetanus
Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine
This study evaluates the immunogenicity and safety of Infanrix hexa™ (DTPa-HBV-IPV/Hib) when administered as a primary vaccination course to Indian infants according to a 6-10-14 weeks or a 2-4-6 months schedule.
- Conditions
- Poliomyelitis, Tetanus, Acellular Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT01353703
- Testing
- Infanrix hexa™
- Where
- 4 sites in India
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.
- Trial name
- NCT02881008
- Testing
- Entecavir, Myrcludex B
- Where
- 9 sites in Russia
- Volunteers
- 48 people
- Sponsor
- Hepatera Ltd.
Chronic Hepatitis B
PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients
This study intends to investigate whether addition of PEG-IFN alfa-2a in HBeAg-negative chronic hepatitis B patients who are pretreated with nucleos(t)ide analogues enhances the degree of HBsAg decline.
- Trial name
- PAS (NCT01373684)
- Testing
- Peginterferon alfa-2a, Nucleos(t)ide analogue
- Where
- 8 sites in Canada, Netherlands
- Volunteers
- 90 people
- Sponsor
- Foundation for Liver Research
Hepatitis C Virus
Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors
Hepatitis C Virus is constantly evolving genetically, particularly in response to the immune system. This is an observational study to examine if immunosuppressants particularly calcineurin inhibitors taken by transplant patients…
- Trial name
- NCT00819026
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Hepatitis B
Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator
This study will look at what happens to the level of protection against hepatitis B (HB) disease if a 'helper' gel is applied to the skin over the injection site of a small dose of hepatitis B vaccine.
- Trial name
- NCT00175435
- Testing
- Resiquimod gel
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease
Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score
This retrospective cohort study evaluated the performance of non-invasive risk scores for predicting de novo hepatocellular carcinoma in adults with hepatitis C virus-related compensated advanced chronic liver disease who…
- Conditions
- Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease, Hepatocellular Carcinoma (HCC)
- Trial name
- HCV-aMAP (NCT07687758)
- Testing
- Non-invasive Risk Score Assessment
- Where
- Thailand
- Volunteers
- 571 people
- Sponsor
- Siriraj Hospital
Hepatocellular Carcinoma, Hepatitis C
Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence
Background and Aims: Arrival of direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) with high-sustained virological response (SVR) rates and very few side effects has drastically changed the management of HCV…
- Conditions
- Hepatocellular Carcinoma, Hepatitis C, Direct Acting Antivirals
- Trial name
- RECAR (NCT03197155)
- Testing
- Direct Acting Antivirals against hepatitis C virus infection
- Volunteers
- 68 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis B, Chronic
A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection
This is a double-blinded, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics, and antiviral activity in both healthy volunteers and volunteers with chronic hepatitis B virus infection.
- Trial name
- NCT04248426
- Testing
- ATI-2173
- Where
- 3 sites in Canada, Moldova and 1 more
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Antios Therapeutics, Inc
Hepatitis C, Liver Disease
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
The primary purpose of this study is to evaluate the pharmacodynamic (i.e. hepatitis C virus (HCV) viral load), pharmacokinetic and safety profiles between two treatment groups receiving different doses of DEB025 in combination…
- Trial name
- NCT02094443
- Testing
- Alisporivir, Ribavirin
- Where
- 16 sites in United States, France
- Volunteers
- 52 people
- Sponsor
- Debiopharm International SA
HIV Infection, Hepatitis B
Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination
The aim of study is to describe the clinical, immunological, serological, virological and therapeutic characteristics of HIV+ patients harboring isolated anti-HBc profile and to assess the response to vaccination in these…
- Trial name
- ANRSHBEP03 (NCT02323308)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 55 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis D
Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment
Pharmacological, single-center, non-profit observational study. The present study is part of a cooperation project between the SC Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Milan…
- Trial name
- MPR_BD (NCT06504485)
- Testing
- Bulevirtide
- Where
- Italy
- Volunteers
- 192 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Hepatitis, Hepatitis C
An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C
The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to Pegasys in combination with ribavirin in the treatment of chronic hepatitis C.
- Trial name
- NCT01889433
- Testing
- Algeron, Pegasys
- Where
- 19 sites in Belarus, India and 2 more
- Volunteers
- 170 people
- Sponsor
- Biocad
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.